Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Eur J Clin Invest ; 54(6): e14174, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38291340

ABSTRACT

BACKGROUND: Amplification of HER2, a receptor tyrosine kinase and a breast cancer-linked oncogene, is associated with aggressive disease. HER2 protein is localised mostly at the cell membrane, but a fraction translocates to mitochondria. Whether and how mitochondrial HER2 contributes to tumorigenicity is currently unknown. METHODS: We enriched the mitochondrial (mt-)HER2 fraction in breast cancer cells using an N-terminal mitochondrial targeting sequence and analysed how this manipulation impacts bioenergetics and tumorigenic properties. The role of the tyrosine kinase activity of mt-HER2 was assessed in wild type, kinase-dead (K753M) and kinase-enhanced (V659E) mtHER2 constructs. RESULTS: We document that mt-HER2 associates with the oxidative phosphorylation system, stimulates bioenergetics and promotes larger respiratory supercomplexes. mt-HER2 enhances proliferation and invasiveness in vitro and tumour growth and metastatic potential in vivo, in a kinase activity-dependent manner. On the other hand, constitutively active mt-HER2 provokes excessive mitochondria ROS generation, sensitises to cell death, and restricts growth of primary tumours, suggesting that regulation of HER2 activity in mitochondria is required for the maximal pro-tumorigenic effect. CONCLUSIONS: mt-HER2 promotes tumorigenicity by supporting bioenergetics and optimal redox balance.


Subject(s)
Breast Neoplasms , Mitochondria , Receptor, ErbB-2 , Mitochondria/metabolism , Humans , Receptor, ErbB-2/metabolism , Breast Neoplasms/metabolism , Breast Neoplasms/genetics , Female , Animals , Cell Line, Tumor , Reactive Oxygen Species/metabolism , Mice , Carcinogenesis/metabolism , Oxidative Phosphorylation , Cell Proliferation , Energy Metabolism , Cell Respiration/physiology
2.
Autophagy ; 18(10): 2409-2426, 2022 Oct.
Article in English | MEDLINE | ID: mdl-35258392

ABSTRACT

Mitochondrial oxidative phosphorylation (OXPHOS) generates ATP, but OXPHOS also supports biosynthesis during proliferation. In contrast, the role of OXPHOS during quiescence, beyond ATP production, is not well understood. Using mouse models of inducible OXPHOS deficiency in all cell types or specifically in the vascular endothelium that negligibly relies on OXPHOS-derived ATP, we show that selectively during quiescence OXPHOS provides oxidative stress resistance by supporting macroautophagy/autophagy. Mechanistically, OXPHOS constitutively generates low levels of endogenous ROS that induce autophagy via attenuation of ATG4B activity, which provides protection from ROS insult. Physiologically, the OXPHOS-autophagy system (i) protects healthy tissue from toxicity of ROS-based anticancer therapy, and (ii) provides ROS resistance in the endothelium, ameliorating systemic LPS-induced inflammation as well as inflammatory bowel disease. Hence, cells acquired mitochondria during evolution to profit from oxidative metabolism, but also built in an autophagy-based ROS-induced protective mechanism to guard against oxidative stress associated with OXPHOS function during quiescence.Abbreviations: AMPK: AMP-activated protein kinase; AOX: alternative oxidase; Baf A: bafilomycin A1; CI, respiratory complexes I; DCF-DA: 2',7'-dichlordihydrofluorescein diacetate; DHE: dihydroethidium; DSS: dextran sodium sulfate; ΔΨmi: mitochondrial inner membrane potential; EdU: 5-ethynyl-2'-deoxyuridine; ETC: electron transport chain; FA: formaldehyde; HUVEC; human umbilical cord endothelial cells; IBD: inflammatory bowel disease; LC3B: microtubule associated protein 1 light chain 3 beta; LPS: lipopolysaccharide; MEFs: mouse embryonic fibroblasts; MTORC1: mechanistic target of rapamycin kinase complex 1; mtDNA: mitochondrial DNA; NAC: N-acetyl cysteine; OXPHOS: oxidative phosphorylation; PCs: proliferating cells; PE: phosphatidylethanolamine; PEITC: phenethyl isothiocyanate; QCs: quiescent cells; ROS: reactive oxygen species; PLA2: phospholipase A2, WB: western blot.


Subject(s)
Autophagy , Inflammatory Bowel Diseases , AMP-Activated Protein Kinases/metabolism , Adenosine Triphosphate/metabolism , Animals , Cysteine/metabolism , DNA, Mitochondrial/metabolism , Dextrans/metabolism , Endothelial Cells/metabolism , Fibroblasts/metabolism , Formaldehyde/metabolism , Humans , Inflammatory Bowel Diseases/metabolism , Isothiocyanates , Lipopolysaccharides/metabolism , Mechanistic Target of Rapamycin Complex 1/metabolism , Mice , Microtubule-Associated Proteins/metabolism , Mitochondria/metabolism , Phosphatidylethanolamines/metabolism , Reactive Oxygen Species/metabolism , Respiration , Sirolimus
3.
Autophagy ; 16(2): 313-333, 2020 02.
Article in English | MEDLINE | ID: mdl-30990357

ABSTRACT

Given the relatively long life of stem cells (SCs), efficient mechanisms of quality control to balance cell survival and resistance to external and internal stress are required. Our objective was to test the relevance of cell quality control mechanisms for SCs maintenance, differentiation and resistance to cell death. We compared cell quality control in P19 stem cells (P19SCs) before and after differentiation (P19dCs). Differentiation of P19SCs resulted in alterations in parameters involved in cell survival and protein homeostasis, including the redox system, cardiolipin and lipid profiles, unfolded protein response, ubiquitin-proteasome and lysosomal systems, and signaling pathways controlling cell growth. In addition, P19SCs pluripotency was correlated with stronger antioxidant protection, modulation of apoptosis, and activation of macroautophagy, which all contributed to preserve SCs quality by increasing the threshold for cell death activation. Furthermore, our findings identify critical roles for the PI3K-AKT-MTOR pathway, as well as autophagic flux and apoptosis regulation in the maintenance of P19SCs pluripotency and differentiation potential.Abbreviations: 3-MA: 3-methyladenine; AKT/protein kinase B: thymoma viral proto-oncogene; AKT1: thymoma viral proto-oncogene 1; ATG: AuTophaGy-related; ATF6: activating transcription factor 6; BAX: BCL2-associated X protein; BBC3/PUMA: BCL2 binding component 3; BCL2: B cell leukemia/lymphoma 2; BNIP3L: BCL2/adenovirus E1B interacting protein 3-like; CASP3: caspase 3; CASP8: caspase 8; CASP9: caspase 9; CL: cardiolipin; CTSB: cathepsin B; CTSD: cathepsin D; DDIT3/CHOP: DNA-damage inducible transcript 3; DNM1L/DRP1: dynamin 1-like; DRAM1: DNA-damage regulated autophagy modulator 1; EIF2AK3/PERK: eukaryotic translation initiation factor 2 alpha kinase 3; EIF2S1/eIF2α: eukaryotic translation initiation factor 2, subunit alpha; ERN1/IRE1α: endoplasmic reticulum to nucleus signaling 1; ESCs: embryonic stem cells; KRT8/TROMA-1: cytokeratin 8; LAMP2A: lysosomal-associated membrane protein 2A; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; NANOG: Nanog homeobox; NAO: 10-N-nonyl acridine orange; NFE2L2/NRF2: nuclear factor, erythroid derived 2, like 2; OPA1: OPA1, mitochondrial dynamin like GTPase; P19dCs: P19 differentiated cells; P19SCs: P19 stem cells; POU5F1/OCT4: POU domain, class 5, transcription factor 1; PtdIns3K: phosphatidylinositol 3-kinase; RA: retinoic acid; ROS: reactive oxygen species; RPS6KB1/p70S6K: ribosomal protein S6 kinase, polypeptide 1; SCs: stem cells; SOD: superoxide dismutase; SHC1-1/p66SHC: src homology 2 domain-containing transforming protein C1, 66 kDa isoform; SOX2: SRY (sex determining region Y)-box 2; SQSTM1/p62: sequestosome 1; SPTAN1/αII-spectrin: spectrin alpha, non-erythrocytic 1; TOMM20: translocase of outer mitochondrial membrane 20; TRP53/p53: transformation related protein 53; TUBB3/betaIII-tubulin: tubulin, beta 3 class III; UPR: unfolded protein response; UPS: ubiquitin-proteasome system.


Subject(s)
Cell Differentiation , Neoplastic Stem Cells/pathology , Activating Transcription Factor 6/metabolism , Animals , Antioxidants/pharmacology , Apoptosis/drug effects , Cardiolipins/metabolism , Caspase Inhibitors/pharmacology , Cell Compartmentation , Cell Differentiation/drug effects , Cell Line, Tumor , Endosomes/metabolism , Endosomes/ultrastructure , Eukaryotic Initiation Factor-2/metabolism , Lipids/chemistry , Lysosomes/metabolism , Lysosomes/ultrastructure , Mice , Mitochondrial Dynamics/drug effects , Mitophagy/drug effects , Neoplastic Stem Cells/drug effects , Neoplastic Stem Cells/ultrastructure , Phosphatidylinositol 3-Kinases/metabolism , Proteolysis/drug effects , Proto-Oncogene Proteins c-akt/metabolism , Signal Transduction/drug effects , TOR Serine-Threonine Kinases/metabolism , Unfolded Protein Response/drug effects
4.
Biol Chem ; 400(2): 141-148, 2019 01 28.
Article in English | MEDLINE | ID: mdl-30281511

ABSTRACT

Mitochondria and oxidative phosphorylation (OXPHOS) are emerging as intriguing targets for the efficient elimination of cancer cells. The specificity of this approach is aided by the capacity of non-proliferating non-cancerous cells to withstand oxidative insult induced by OXPHOS inhibition. Recently we discovered that mitochondrial targeting can also be employed to eliminate senescent cells, where it breaks the interplay between OXPHOS and ATP transporters that appear important for the maintenance of mitochondrial morphology and viability in the senescent setting. Hence, mitochondria/OXPHOS directed pharmacological interventions show promise in several clinically-relevant scenarios that call for selective removal of cancer and senescent cells.


Subject(s)
Cellular Senescence , Mitochondria/metabolism , Neoplasms/pathology , Adenosine Diphosphate/metabolism , Adenosine Triphosphate/metabolism , Biological Transport , Cell Death , Cell Proliferation , Humans , Neoplasms/metabolism , Oxidative Phosphorylation , Reactive Oxygen Species/metabolism
5.
Cell Metab ; 29(2): 399-416.e10, 2019 02 05.
Article in English | MEDLINE | ID: mdl-30449682

ABSTRACT

Cancer cells without mitochondrial DNA (mtDNA) do not form tumors unless they reconstitute oxidative phosphorylation (OXPHOS) by mitochondria acquired from host stroma. To understand why functional respiration is crucial for tumorigenesis, we used time-resolved analysis of tumor formation by mtDNA-depleted cells and genetic manipulations of OXPHOS. We show that pyrimidine biosynthesis dependent on respiration-linked dihydroorotate dehydrogenase (DHODH) is required to overcome cell-cycle arrest, while mitochondrial ATP generation is dispensable for tumorigenesis. Latent DHODH in mtDNA-deficient cells is fully activated with restoration of complex III/IV activity and coenzyme Q redox-cycling after mitochondrial transfer, or by introduction of an alternative oxidase. Further, deletion of DHODH interferes with tumor formation in cells with fully functional OXPHOS, while disruption of mitochondrial ATP synthase has little effect. Our results show that DHODH-driven pyrimidine biosynthesis is an essential pathway linking respiration to tumorigenesis, pointing to inhibitors of DHODH as potential anti-cancer agents.


Subject(s)
DNA, Mitochondrial/metabolism , Mitochondria/metabolism , Neoplasms/metabolism , Oxidoreductases Acting on CH-CH Group Donors/physiology , Pyrimidines/metabolism , Animals , Cell Line, Tumor , Cell Respiration , Dihydroorotate Dehydrogenase , Humans , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Oxidative Phosphorylation , Ubiquinone/metabolism
6.
Semin Cancer Biol ; 47: 18-28, 2017 12.
Article in English | MEDLINE | ID: mdl-28673608

ABSTRACT

Cancer stem cells (CSCs) have been suggested to be responsible for tumor re-growth and relapse. Physiological and morphological knowledge of CSCs may be essential for the development of new therapeutic strategies targeting cancer development, progression, and recurrence. Current research is focused on a deeper understanding of CSCs metabolic profiles, taking into consideration their energy demands. Energy metabolism and mitochondrial function are important factors operating on stemness maintenance and cell fate specification. Due to the role of mitochondria as central hubs in the overall cell metabolism and death and survival pathways, research on their physiology in CSCs is of paramount importance to decipher mechanisms underlying their therapy-resistant phenotype. In this review, we focus on CSCs mitochondrial biology and mitochondria-related signaling pathways that contribute to CSCs survival and maintenance, thereby representing possible therapeutic targets.


Subject(s)
Mitochondria/metabolism , Neoplasms/metabolism , Neoplastic Stem Cells/metabolism , Animals , Energy Metabolism/drug effects , Humans , Mitochondria/drug effects , Molecular Targeted Therapy , Neoplasms/drug therapy , Neoplasms/etiology , Neoplastic Stem Cells/drug effects , Signal Transduction/drug effects , Stem Cells/metabolism
7.
Arch Toxicol ; 91(3): 1261-1278, 2017 Mar.
Article in English | MEDLINE | ID: mdl-27358235

ABSTRACT

Sirtuins regulate several processes associated with tumor development. Resveratrol was shown to stimulate sirtuin 1 and 3 (SIRT1/3) activities and to result in cytotoxicity for some tumor types. The relationship between modulation of sirtuin activities, cellular metabolic remodeling and resveratrol cytotoxicity mechanism on breast cancer cells is still an open question. Here, we evaluated whether sirtuin 1 and 3 are involved in resveratrol toxicity and whether resveratrol leads to a metabolic remodeling and cell differentiation. Results using the Extracellular Flux Analyzer indicated that resveratrol inhibits mitochondrial respiration in breast cancer cells. We also demonstrated here for the first time that resveratrol cytotoxic effects on breast cancer cells were modulated by SIRT1 and also involved mitochondrial complex I inhibition. Importantly, we also demonstrated that resveratrol reduced the pool of breast cancer cells with stemness markers through a SIRT1-dependent mechanism. Our data highlights the role of SIRT1 in regulating resveratrol induced differentiation and/or toxicity in breast cancer cells.


Subject(s)
Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Sirtuin 1/metabolism , Stilbenes/pharmacology , Animals , Antineoplastic Agents, Phytogenic/pharmacology , Breast Neoplasms/metabolism , Cell Cycle Checkpoints/drug effects , Cell Differentiation/drug effects , Cell Respiration/drug effects , Electron Transport Complex I/antagonists & inhibitors , Electron Transport Complex I/metabolism , Female , Humans , MCF-7 Cells/drug effects , MCF-7 Cells/metabolism , Male , Mitochondria, Liver/drug effects , Mitochondria, Liver/metabolism , Neoplastic Stem Cells/drug effects , Neoplastic Stem Cells/metabolism , Neoplastic Stem Cells/pathology , Rats, Wistar , Resveratrol , Sirtuin 1/genetics , Sirtuin 3/genetics , Sirtuin 3/metabolism
8.
Mitochondrion ; 30: 95-104, 2016 09.
Article in English | MEDLINE | ID: mdl-27423789

ABSTRACT

AIMS: It is still unclear why anthracycline treatment results in a cardiac-specific myopathy. We investigated whether selective doxorubicin (DOX) cardiotoxicity involving mitochondrial degeneration is explained by different respiratory complexes reserves between tissues by comparing and contrasting treatment effects in heart vs liver and kidney. Alternatively, we have also explored if the degeneration is due to alterations of mitochondrial thresholds to incompatible states. METHODS AND RESULTS: Heart, liver and kidney mitochondria were isolated from male Wistar rats weekly injected with DOX during 7weeks. Global flux and isolated step curves were obtained for Complex I, III, IV, as well as for the adenine nucleotide translocator. We show treatment-related alterations in global flux curve for Complex III in all analyzed tissues and in Complex IV activity curve solely in heart. However, all mitochondrial threshold curves remained unchanged after treatment in the analyzed tissues. No treatment-related differences were detected on transcript or protein analysis of selected respiratory complexes subunits. However, a specific loss of cytochrome c and cardiolipin was measured in heart, but not in other organs, mitochondria from DOX-treated animals. CONCLUSIONS: Contrary to our hypothesis, impaired mitochondrial respiration could not be explained by intrinsic differences in respiratory complexes reserves among tissues or, by alterations in mitochondrial thresholds after treatment. Instead, we propose that loss of cytochrome c and cardiolipin are responsible for the depressed mitochondrial respiration observed after chronic DOX treatment. Moreover, cardiac cytochrome c and cardiolipin depletion decreases metabolic network buffering, hindering cardiac ability to respond to increased workload, accelerating cardiac aging.


Subject(s)
Antibiotics, Antineoplastic/adverse effects , Cardiolipins/analysis , Cytochromes c/analysis , Doxorubicin/adverse effects , Mitochondria/drug effects , Mitochondrial Myopathies/pathology , Myocardium/pathology , Animals , Antibiotics, Antineoplastic/administration & dosage , Doxorubicin/administration & dosage , Kidney/pathology , Liver/pathology , Male , Rats, Wistar
9.
Eur J Clin Invest ; 46(3): 285-98, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26782788

ABSTRACT

BACKGROUND: The employment of dietary strategies such as ketogenic diets, which force cells to alter their energy source, has shown efficacy in the treatment of several diseases. Ketogenic diets are composed of high fat, moderate protein and low carbohydrates, which favour mitochondrial respiration rather than glycolysis for energy metabolism. DESIGN: This review focuses on how oncological, neurological and mitochondrial disorders have been targeted by ketogenic diets, their metabolic effects, and the possible mechanisms of action on mitochondrial energy homeostasis. The beneficial and adverse effects of the ketogenic diets are also highlighted. RESULTS AND CONCLUSIONS: Although the full mechanism by which ketogenic diets improve oncological and neurological conditions still remains to be elucidated, their clinical efficacy has attracted many new followers, and ketogenic diets can be a good option as a co-adjuvant therapy, depending on the situation and the extent of the disease.


Subject(s)
Diet, Ketogenic/methods , Epilepsy/diet therapy , Mitochondrial Diseases/diet therapy , Neoplasms/diet therapy , Energy Metabolism , Glycolysis , Humans , Mitochondria/metabolism , Nervous System Diseases/diet therapy
10.
Curr Protoc Toxicol ; 65: 25.5.1-25.5.16, 2015 Aug 06.
Article in English | MEDLINE | ID: mdl-26250398

ABSTRACT

Mitochondrial bioenergetics is based on the generation of the protonmotive force by the electron transport chain. The protonmotive force is used by mitochondria for different critical aspects of its normal function, ranging from calcium accumulation to the synthesis of ATP. The transmembrane electric potential (ΔΨ) is the major component of the protonmotive force and is also the main responsible for ATP synthesis by mitochondrial ATP synthase. Although several methods can be used to measure the ΔΨ, the use of the tetraphenylphosphonium cation (TPP(+))-selective electrode is still a method of election due to its sensitivity. The method is based on the accumulation of TPP(+) by energized mitochondria, which develop a negative charge in the matrix due to the ejection of protons. This unit describes how to build a custom-made TPP(+)-selective electrode and how to establish the necessary set-up to follow ΔΨ fluctuations in isolated mitochondrial fractions.


Subject(s)
Membrane Potential, Mitochondrial/physiology , Mitochondria/physiology , Onium Compounds/metabolism , Organophosphorus Compounds/metabolism , Electrophysiology/methods , Ion-Selective Electrodes , Mitochondrial Membrane Transport Proteins , Mitochondrial Permeability Transition Pore , Onium Compounds/chemistry , Organophosphorus Compounds/chemistry , Subcellular Fractions
11.
Oncotarget ; 6(19): 17081-96, 2015 Jul 10.
Article in English | MEDLINE | ID: mdl-26025920

ABSTRACT

Although melatonin oncostatic and cytotoxic effects have been described in different types of cancer cells, the specific mechanisms leading to its antitumoral effects and their metabolic context specificity are still not completely understood. Here, we evaluated the effects of melatonin in P19 embryonal carcinoma stem cells (CSCs) and in their differentiated counterparts, cultured in either high glucose medium or in a galactose (glucose-free) medium which leads to glycolytic suppression and increased mitochondrial metabolism. We found that highly glycolytic P19 CSCs were less susceptible to melatonin antitumoral effects while cell populations relying on oxidative metabolism for ATP production were more affected. The observed antiproliferative action of melatonin was associated with an arrest at S-phase, decreased oxygen consumption, down-regulation of BCL-2 expression and an increase in oxidative stress culminating with caspase-3-independent cell death. Interestingly, the combined treatment of melatonin and dichloroacetate had a synergistic effect in cells grown in the galactose medium and resulted in an inhibitory effect in the highly resistant P19 CSCs. Melatonin appears to exert its antiproliferative activity in P19 carcinoma cells through a mitochondrially-mediated action which in turn allows the amplification of the effects of dichloroacetate, even in cells with a more glycolytic phenotype.


Subject(s)
Antineoplastic Agents/pharmacology , Embryonal Carcinoma Stem Cells/drug effects , Melatonin/pharmacology , Neoplastic Stem Cells/drug effects , Blotting, Western , Cell Line, Tumor , Cell Proliferation/drug effects , Embryonal Carcinoma Stem Cells/metabolism , Humans , Membrane Potential, Mitochondrial/drug effects , Mitochondria/drug effects , Neoplastic Stem Cells/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...